Free Cash Flow

A new report reveals a puzzling slowdown in CLO issuance despite low credit yields. Experts analyze the hidden headwinds and shifting investor strategies.

Canadians lost over $704 million to scams in 2025, but that's just the tip of the iceberg. A new multi-agency campaign tackles the hidden crisis.

Dr. Pietro Garbelli's award-winning book offers a crucial roadmap for responsibly integrating AI, balancing high-tech innovation with patient trust.

Canada's busiest airport saw modest passenger growth and strong financials in 2025, navigating supply chain woes, labor strife, and shifting travel trends.

Tsakos Energy Navigation reports a 200% Q4 income jump, capitalizing on high tanker rates while investing in a new fleet of LNG and VLCC vessels.

With its key earnings call on March 12, Aemetis's recent tax credit sales and project milestones are weighed against past financial performance.

Brazilian aerospace giant Embraer shatters financial records and builds its largest-ever order book, signaling a robust recovery in global aviation.

Advantage Energy posts record 2025 results, slashing debt while boosting output and pioneering a major carbon capture project. What's next for the firm?

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

The outdoor gear company reports lower 2025 sales and a net loss but achieves adjusted profit and a debt-free balance sheet on its path to transformation.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

El Pollo Loco is testing five bold new menu items. We dive into the strategy, the competition, and what it means for the fast-casual chicken wars.

As Concentrix sets its Q1 earnings date, investors are watching closely to see if its AI-driven strategy can overcome market headwinds and cautious guidance.

With FDA Breakthrough status for its MASH drug, a new CEO, and a fortified balance sheet, Altimmune is poised to take on serious liver disease and addiction.

Investors eye Moody's CEO Rob Fauber's upcoming speech for insights on AI strategy, M&A forecasts, and navigating an increasingly complex global economy.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Ad-tech giant Teads reports massive revenue growth post-merger, but a $352M impairment and restructuring signal deep integration challenges.

Following key acquisitions, the AI firm pivots to a vertically integrated defense powerhouse, forecasting explosive growth backed by a swelling order backlog.

German defense tech firm RENK Group reports a record €1.37B revenue, fueled by a 24% surge in its defense business amid global geopolitical tensions.

Strong 2025 results, aggressive share buybacks, and major growth projects define Athabasca's strategy. A deep dive into the company's future.